The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
750
28-Day All-cause mortality
Time frame: 28 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Tuscon, Arizona, United States
Unnamed facility
Bakersfield, California, United States
Unnamed facility
Colton, California, United States
Unnamed facility
Loma Linda, California, United States
Unnamed facility
Long Beach, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Rancho Mirage, California, United States
Unnamed facility
San Diego, California, United States
...and 52 more locations